Please login to the form below

Not currently logged in
Email:
Password:

galcanezumab

This page shows the latest galcanezumab news and features for those working in and with pharma, biotech and healthcare.

Biohaven gets FDA approval for migraine drug Nurtec ODT

Biohaven gets FDA approval for migraine drug Nurtec ODT

s Emgality (galcanezumab) – as well as Lundbeck’s just-approved intravenous therapy Vyepti (eptinezumab).

Latest news

More from news
Approximately 1 fully matching, plus 21 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics